权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

ReCAPSE: Recurrence from Claims And PROs for SEER Enhancement

ReCAPSE：SEER 增强的索赔和 PRO 的复发

基本信息

批准号：
10428568
负责人：
Jessica Chubak
金额：
$ 56.77万
依托单位：
FRED HUTCHINSON CANCER CENTER
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-25 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10428568
关键词：
Accounting Address Agreement Algorithms Area Breast Cancer Patient Cancer Burden Cancer Center Cancer Survivor Clinical Collaborations Computerized Medical Record Confidentiality of Patient Information Controlled Clinical Trials Data Diagnosis Disease Disease Management Disease remission Electronic Health Record Enrollment Environment Event Frequencies Future Glare Goals Gold Health Insurance Health Maintenance Organizations Health Technology Incidence Individual Insurance Intervention Kentucky Lead Link Malignant Neoplasms Medical Medical Records Medicare National Cancer Institute Outcome Participant Patient Outcomes Assessments Patient Representative Patient Self-Report Patients Pattern Performance Phase Policies Population Prevalence Provider Quality Indicator Quality of life Recording of previous events Records Recurrence Registries Reproducibility Research Resources Risk SEER Program Sampling Science Site Specific qualifier value Specificity Subgroup System Technology Time Treatment/Psychosocial Effects Universities Validation Vision Visual Woman Work base breast cancer diagnosis cancer recurrence cancer therapy case control cohort cost dashboard data quality data registry design effectiveness study experience flexibility implementation tool improved innovation insurance claims malignant breast neoplasm mobile application mortality multidisciplinary neoplasm registry neoplasm resource novel patient health information population based population health preservation prevent prognostic sound statistics tool tool development tumor

项目摘要

PROJECT SUMMARY The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute serves as a national dashboard for cancer surveillance and is an authoritative resource for cancer incidence and mortality rates. However, the registry lacks information on cancer recurrence, which is a major outcome impacting decisions and policies around management of disease at both the individual and the population levels. The goal of the proposed study is to develop a scalable approach for population-based ascertainment of cancer recurrence with a specific focus on breast cancer. The first (UG3) phase of the study will develop an innovative algorithm for detecting a first recurrence by combining medical claims with patient reported outcomes (PROs). This phase will be conducted in collaboration with the Seattle-Puget Sound SEER registry and will leverage ongoing research agreements with Puget Sound payers. Different algorithms will be developed to allow for flexibility in maximizing sensitivity or specificity. The algorithms will be validated against gold-standard recurrence information based on electronic medical records from two major local providers. Study participants will consistent of stage I-III breast cancer patients diagnosed in 2013–2016 on whom “gold standard” information on recurrence is available. A retrospective case-control design will be employed in which an equal number of recurrent cases and non-recurrent controls at each validation site will be solicited for PROs regarding their recurrence histories. All validation activities will explicitly adjust for missing data resulting from participant non-response to the PRO solicitation. The second (UH3) phase will be conducted in collaboration with the Kentucky Cancer Registry. The algorithms developed in the UG3 phase will be deployed on all Kentucky stage I-III breast cancer diagnoses in 2015–2017 on whom claims data are available. This phase will include a validation against medical records from patients diagnosed at the University of Kentucky Markey Cancer Center over a concurrent period. In this phase, the study team will develop a visual interface for summarizing recurrence risks overall and within specified prognostic subgroups. The interface will allow users to examine representativeness of the patient cohort used to estimate recurrence risks and will also provide estimates that are adjusted for participant non-response. The proposed work will represent a pioneering effort that establish whether medical claims data combined with patient self-report constitute a promising avenue towards determining whether the critical endpoint of cancer recurrence can be added to population-based cancer registries.

项目总结